- 中文名稱
Eculizumab 生物類似藥, 人 C5 單克隆抗體
- 英文名字
- Eculizumab Biosimilar, Human C5 Monoclonal Antibody
- 供應(yīng)商
- Promab
- 產(chǎn)品貨號(hào)
- PMB-B00016
- 產(chǎn)品報(bào)價(jià)
- ￥詢價(jià)/1mg/5mg/20mg
- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購(gòu)買方式
- 90%產(chǎn)品中國(guó)有現(xiàn)貨庫(kù)存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868
- 產(chǎn)品新聞
- 背景資料
- Eculizumab, a recombinant humanized anti-C5 (the terminal Complement component 5) monoclonal antibody, selectively targets and inhibits the terminal portion of the complement cascade. Eculizumab is a first-in-class terminal complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) with excessive destruction of red blood cells (hemolysis). Eculizumab is also the first agent to treat atypical hemolytic uremic syndrome (aHUS) with abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.nnThe complement immune system destroys and removes foreign particles by the complement cascade triggered by foreign particles. The complement proteins activiated in order create holes or pores in the invading organisms, leading to their destruction. The complement immune system in patients can also destroy healthy cells and tissue, resulting in excessive destruction of red blood cells (hemolysis) or abnormal blood clots to form in small blood vessels throughout the body.nnWhen activated, C5 at a late stage in the complement cascade is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also destroying cells by triggering pore formation. Eculizumab specifically binds to C5 and inhibits the cleavage of C5 to C5a (a potent anaphylatoxin with prothrombotic and proinflammatory properties) and C5b by the C5 convertase, preventing the generation of the terminal complement complex C5b-9 (which also has prothrombotic and proinflammatory effects). Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. By doing so, the normal, disease-preventing functions of proximal complement system are largely preserved, while the properties of C5 that promote inflammation and cell destruction are impeded.
- 應(yīng)用類型
- Flow cytometry, animal model study
- 免疫原
- Human C5
- 來源宿主
- CHO cells
- 反應(yīng)性
- Human
- 保存建議
- Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
- 其他
- ProMab 生物技術(shù)公司通過整合生物信息學(xué)、分子生物學(xué)、蛋白質(zhì)表達(dá)、純化技術(shù)、基因克隆、微生物學(xué)和免疫學(xué)，利用新型高通量技術(shù)開發(fā)重組蛋白、抗體和工程細(xì)胞系并將其商業(yè)化。專注于免疫治療領(lǐng)域，特別是 CAR-T/NK 細(xì)胞技術(shù)。ProMab 還開發(fā)了一種新型的 mRNA 脂質(zhì)納米顆粒（mRNA-LNP）平臺(tái)，用于即用型試劑和定制研究服務(wù)，以推進(jìn)現(xiàn)有產(chǎn)品并擴(kuò)展到更多的研究領(lǐng)域。
- 注意
-
該頁(yè)面的中文產(chǎn)品信息的翻譯，僅供參考。準(zhǔn)確的產(chǎn)品信息請(qǐng)以廠家的英文說明書為準(zhǔn)。下單前，請(qǐng)瀏覽說明書確認(rèn)。
-
